Sagimet Biosciences, Inc. Class A Statistics
Want to see SGMT full AI Analyst Report?
Sagimet Biosciences, Inc. Class A (SGMT) Stock Statistics & Valuation Metrics
Total Valuation
Sagimet Biosciences, Inc. Class A has a market cap or net worth of $718.89M. The enterprise value is $381.53M.
- Market Cap
- $718.89M
- Enterprise Value
- $381.53M
Share Statistics
Sagimet Biosciences, Inc. Class A has 70,341,170 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 70,341,170
- Owned by Insiders
- 4.64%
- Owned by Institutions
- 48.29%
Financial Efficiency
Sagimet Biosciences, Inc. Class A’s return on equity (ROE) is -0.46 and return on invested capital (ROIC) is -51.04%.
- Return on Equity (ROE)
- -0.46
- Return on Assets (ROA)
- -0.44
- Return on Invested Capital (ROIC)
- -51.04%
- Return on Capital Employed (ROCE)
- -0.51
- Revenue Per Employee
- 0
- Profits Per Employee
- -3.19M
- Employee Count
- 16
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Sagimet Biosciences, Inc. Class A is -8.59. Sagimet Biosciences, Inc. Class A’s PEG ratio is -0.20.
- PE Ratio
- -8.59
- PS Ratio
- 0.00
- PB Ratio
- 2.63
- Price to FCF
- -7.70
- Price to Operating Cash Flow
- -14.73
- PEG Ratio
- -0.20
Income Statement
In the last 12 months, Sagimet Biosciences, Inc. Class A had revenue of 0 and earned -51.04M in profits. Earnings per share was -1.58.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -56.89M
- Pretax Income
- -51.04M
- Net Income
- -51.04M
- EBITDA
- -51.04M
- Earnings Per Share (EPS)
- -1.58
Cash Flow
In the last 12 months, operating cash flow was -43.25M and capital expenditures 0, giving a free cash flow of -43.25M billion.
- Operating Cash Flow
- -43.25M
- Free Cash Flow
- -43.25M
- Free Cash Flow per Share
- -0.69
Dividends & Yields
Sagimet Biosciences, Inc. Class A pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.07%
- Earnings Yield
- -8.44%
Stock Price Statistics
- Beta
- 2.64
- 52-Week Price Change
- 32.04%
- 50-Day Moving Average
- 9.88
- 200-Day Moving Average
- 7.73
- Relative Strength Index (RSI)
- 51.81
- Average Volume (3m)
- 1.25M
Important Dates
Sagimet Biosciences, Inc. Class A upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
Sagimet Biosciences, Inc. Class A as a current ratio of 22.82, with Debt / Equity ratio of 0.07%
- Current Ratio
- 22.82
- Quick Ratio
- 22.82
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.68
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Sagimet Biosciences, Inc. Class A has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Sagimet Biosciences, Inc. Class A EV to EBITDA ratio is -10.79, with an EV/FCF ratio of -13.96.
- EV to Sales
- 0.00
- EV to EBITDA
- -10.79
- EV to Free Cash Flow
- -13.96
- EV to Operating Cash Flow
- -13.96
Balance Sheet
Sagimet Biosciences, Inc. Class A has $236.40M in cash and marketable securities with $2.02M in debt, giving a net cash position of $234.38M billion.
- Cash & Marketable Securities
- $236.40M
- Total Debt
- $2.02M
- Net Cash
- $234.38M
- Net Cash Per Share
- $3.33
- Tangible Book Value Per Share
- $3.88
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Sagimet Biosciences, Inc. Class A is $27.16, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $27.16
- Price Target Upside
- 165.77% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 13
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 33.38%
Scores
- Smart Score
- 7
- AI Score
- 58

